Evidence map›Paper›PMID 41213913›Full record

ArticleNature communications2025

Breaking barriers in crosslinking mass spectrometry with enhanced throughput and sensitivity using Orbitrap Astral.

Fränze Müller, Micha J Birklbauer, Julia Bubis, Karel Stejskal, Viktoria Dorfer, Karl Mechtler

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fränze MüllerResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria. fraenze.mueller@imp.ac.at.ORCID http://orcid.org/0000-0003-3764-3547
Micha J BirklbauerBioinformatics Research Group, University of Applied Sciences Upper Austria, Hagenberg, Upper Austria, Austria.ORCID http://orcid.org/0009-0005-1051-179X
Julia BubisResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Karel StejskalInstitute of Molecular Biotechnology (IMBA), Vienna BioCenter (VBC), Vienna, Austria.
Viktoria DorferBioinformatics Research Group, University of Applied Sciences Upper Austria, Hagenberg, Upper Austria, Austria. viktoria.dorfer@fh-hagenberg.at.ORCID http://orcid.org/0000-0002-5332-5701
Karl MechtlerResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria. karl.mechtler@imp.ac.at.ORCID http://orcid.org/0000-0002-3392-9946

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) Grant DOI 10.55776/ESP497Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) Grant-DOI 10.55776/F88Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) Grant DOI 10.55776/P3504
6 · The paper itself

Abstract

Crosslinking mass spectrometry is an essential tool for probing protein-protein interactions and structural organization. We here compare Orbitrap Astral and Orbitrap Eclipse instruments using Cas9 crosslinked with PhoX and DSSO under standardized chromatographic and acquisition conditions. The Astral identifies over 40% more unique residue pairs, largely due to increased MS1 sensitivity and efficient detection of low-abundance precursors. Implementation of high-field asymmetric ion mobility spectrometry further increases identifications by 30% through improved precursor filtering. On the Astral, single higher-energy collisional dissociation consistently outperforms stepped fragmentation, particularly at low sample amounts, whereas the Eclipse shows minimal dependence on fragmentation strategy. Gradient optimization experiments demonstrate that longer separations enhance identifications in purified crosslinked samples, while gains plateau in complex backgrounds, indicating the need for enrichment or isolation strategies. Column comparisons show that pore size and particle diameter affect separation efficiency, with the Aurora Ultimate column yielding sharper peaks and more crosslink identifications than PepMap. Together, these findings emphasize that instrument choice, fragmentation mode, and chromatographic design directly influence crosslinking performance. The Astral's combination of sensitivity and scan speed supports comprehensive detection of low-abundance crosslinks, providing deeper structural coverage of protein interaction networks.

Indexed as

Cross-Linking ReagentsMass SpectrometryHumansProteomicsCross-Linking Reagents

Identifiers

PMID41213913
PMCPMC12603054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.